APCAM-CLDM: After Cancer in the Military: What Happens After Long-term Sick Leave

Sponsor
Direction Centrale du Service de Santé des Armées (Other)
Overall Status
Recruiting
CT.gov ID
NCT05235022
Collaborator
(none)
50
1
11.9
4.2

Study Details

Study Description

Brief Summary

In recent decades, early diagnosis and improved treatment have led to increased survival for most people with cancer. This improved survival has led to more attention being paid to the quality of life of these people, and to their reintegration into social and professional life. In France, 3.8 million people are treated or in remission from cancer in 2017. Among the 400,000 new patients diagnosed with cancer each year in France, 160,000 (40%) are in professional activity.

Cancer treatments induce after-effects that can be felt several months or even years after the diagnosis and have an impact on life. In a study of patients in remission from cancer at 12 months after diagnosis, 47 to 53% of patients had changed jobs or stopped working. In another Finnish study, 26% of patients had decreased physical ability and 19% had decreased mental ability to work five years after cancer diagnosis.

In France, studies that have evaluated the impact of cancer on employment and the factors associated with return to work after cancer are still rare: the VICAN study showed that among people in work at the time of diagnosis, 20% were no longer working five years later.

With an estimated annual incidence of approximately 400 new cancers per year, the military population is also affected by cancer. Professional reintegration after cancer is of particular concern to the military. The specificity and requirements of the military condition can indeed make this reintegration more difficult. Regular or even intense physical activity is indeed essential but can be difficult after undergoing anti-cancer treatments. Moreover, external operations and many activities are conditioned by the obtaining of medical skills, which are sometimes incompatible with the state of health of patients recently treated for a neoplastic pathology. The studies previously carried out concerning the professional future after cancer do not seem to us to be transposable to the military population. To our knowledge, no study has evaluated occupational reintegration in military personnel after cancer.

The aim of this study is to evaluate the difficulties encountered during the post-cancer professional reintegration of military personnel in terms of fatigue, aptitude and advancement, in order to anticipate them and possibly remedy them. The identification of these difficulties will eventually allow to anticipate them and possibly to remedy them via an adapted post-cancer professional reintegration pathway.

Condition or Disease Intervention/Treatment Phase
  • Other: Questionnaires

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
After Cancer in the Military: What Happens After Long-term Sick Leave
Actual Study Start Date :
Mar 3, 2022
Anticipated Primary Completion Date :
Mar 1, 2023
Anticipated Study Completion Date :
Mar 1, 2023

Outcome Measures

Primary Outcome Measures

  1. Description of the difficulties reported by the patients during their return to work after cancer [Until the end of the study (12 months)]

    The primary outcome measure is descriptive. The purpose is to highlight the difficulties most often mentioned by patients during the interview.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • French military personnel who were placed on long-term sick leave for the management of a tumor pathology between January 2015 and December 2020,

  • French-speaking.

Exclusion Criteria:
  • Under 18 years old

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpital d'Instruction des Armées Sainte-Anne Toulon France 83800

Sponsors and Collaborators

  • Direction Centrale du Service de Santé des Armées

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Direction Centrale du Service de Santé des Armées
ClinicalTrials.gov Identifier:
NCT05235022
Other Study ID Numbers:
  • 2021PPRC07
  • 2021-A02180-41
First Posted:
Feb 10, 2022
Last Update Posted:
Mar 18, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Direction Centrale du Service de Santé des Armées

Study Results

No Results Posted as of Mar 18, 2022